The Global Asthma Network rationale and methods for Phase I global surveillance: prevalence, severity, management and risk factors. by Ellwood, P et al.
Ellwood, P; Asher, MI; Billo, NE; Bissell, K; Chiang, CY; Ellwood,
EM; El-Sony, A; Garca-Marcos, L; Mallol, J; Marks, GB; Pearce,
NE; Strachan, DP (2017) The Global Asthma Network rationale and
methods for Phase I global surveillance: prevalence, severity, man-
agement and risk factors. The European respiratory journal, 49 (1).
ISSN 0903-1936 DOI: 10.1183/13993003.01605-2016
Downloaded from: http://researchonline.lshtm.ac.uk/3353022/
DOI: 10.1183/13993003.01605-2016
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: http://creativecommons.org/licenses/by/2.5/
The Global Asthma Network rationale and
methods for Phase I global surveillance:
prevalence, severity, management and
risk factors
Philippa Ellwood 1, M. Innes Asher1, Nils E. Billo2, Karen Bissell3,4,
Chen-Yuan Chiang4,5,6, Eamon M. Ellwood1, Asma El-Sony7,
Luis García-Marcos8, Javier Mallol9, Guy B. Marks10, Neil E. Pearce11 and
David P. Strachan12
Affiliations: 1Paediatrics: Child and Youth Health, The University of Auckland, Auckland, New Zealand.
2Joensuu, Finland. 3International Union Against Tuberculosis and Lung Disease (The Union), Paris, France.
4School of Population Health, The University of Auckland, Auckland, New Zealand. 5Division of Pulmonary
Medicine, Dept of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan. 6Internal
Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan. 7Epidemiological
Laboratory (Epi-Lab) for Public Health, Research and Development, Khartoum, Sudan. 8Paediatric Allergy and
Pulmonology Units, Arrixaca University Children’s Hospital, University of Murcia and IMIB Bioresearch
Institute, Murcia, Spain. 9Paediatric Respiratory Medicine, Hospital-CRS El Pino, University of Santiago de
Chile, (USACH), Santiago, Chile. 10Dept of Medical Statistics, Respiratory and Environmental Epidemiology,
South Western Sydney Clinical School, University of New South Wales, Sydney, Australia. 11Faculty of
Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK.
12Population Health Research Institute, St George’s, University of London, London, UK.
Correspondence: Philippa Ellwood, The University of Auckland, Paediatrics: Child and Youth Health, Private
Bag 92019, Auckland 1301, New Zealand. E-mail: p.ellwood@auckland.ac.nz
@ERSpublications
The Global Asthma Network undertakes global studies of asthma surveillance, management and risk
factors http://ow.ly/h67s305t9vS
Cite this article as: Ellwood P, Asher MI, Billo NE, et al. The Global Asthma Network rationale and
methods for Phase I global surveillance: prevalence, severity, management and risk factors. Eur Respir J
2017; 49: 1601605 [https://doi.org/10.1183/13993003.01605-2016].
ABSTRACT The Global Asthma Network (GAN), established in 2012, followed the International Study of
Asthma and Allergies in Childhood (ISAAC). ISAAC Phase One involved over 700 000 adolescents and
children from 156 centres in 56 countries; it found marked worldwide variation in symptom prevalence of
asthma, rhinitis and eczema that was not explained by the current understanding of these diseases; ISAAC
Phase Three involved over 1 187 496 adolescents and children (237 centres in 98 countries). It found that
asthma symptom prevalence was increasing in many locations especially in low- and middle-income countries
where severity was also high, and identified several environmental factors that required further investigation.
GAN Phase I, described in this article, builds on the ISAAC findings by collecting further information on
asthma, rhinitis and eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital
admissions, management and use of asthma essential medicines. The subjects will be the same age groups as
ISAAC, and their parents. In this first global monitoring of asthma in children and adults since 2003, further
evidence will be obtained to understand asthma, management practices and risk factors, leading to further
recognition that asthma is an important non-communicable disease and to reduce its global burden.
This article has supplementary material available from erj.ersjournals.com
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Introduction
An estimated 241 million people in all parts of the world suffer from asthma [1], and nearly 1000 people
per day die from asthma [2]. The Global Asthma Network (GAN) [3] was established in 2012 to improve
asthma care globally, with a focus on low- and middle-income countries, through enhanced surveillance,
research collaboration, capacity building and access to quality-assured, affordable, essential asthma
medicines. GAN was formed by scientists from the International Study of Asthma and Allergies in
childhood (ISAAC) 1991–2012 (Phases One [4], Two [5] and Three [6]) and from the International
Union Against Tuberculosis and Lung Disease (The Union) following production of the first Global
Asthma Report (GAR) 2011 [7], launched in New York (NY, USA) in 2011 at the time of the United
Nations High-Level meeting on non-communicable diseases. A second GAR [8], written and produced by
GAN in 2014 was launched in October at the 45th Union World Conference on Lung Health, Barcelona,
Spain. These reports highlight the existing evidence of the burden of asthma, provide evidence-based
recommendations for cost-effective health improvement, especially in low- and middle-income countries
and advocate for increasing the priority given to interventions for asthma.
ISAAC Phase One (1994–1995) identified large variations in the prevalence of symptoms of asthma, rhinitis
and eczema, with differences of between 20-fold and 60-fold between centres, showing marked differences
in asthma prevalence in populations with similar genetic or ethnic backgrounds [9], suggesting that
environmental risk factors in the broadest sense were the major determinants of the prevalence of asthma
in a community. ISAAC Phase Three (2001–2003) examined time trends and included new questions on
risk factors which identified many environmental associations [10]. These were the last ISAAC studies.
The Union implemented asthma pilot projects in Benin [11], China (Huaiyuan County) [12], El Salvador
[13] and Sudan [14]. These projects found that inhaled corticosteroids were not available in any of these
sites in the public sector and that asthma was greatly underdiagnosed. The Union’s Asthma Drug Facility
enabled countries to purchase quality-assured essential affordable asthma medicines; and inhaled
corticosteroids became widely used, resulting in a reduction in hospitalisations [15, 16].
GAN Phase I is a development from ISAAC (particularly Phases One [17–21] and Three [22–24]), and
The Union [11, 12, 14, 25]. GAN Phase I has extended its surveillance to include adults, for whom there
are limited global data, and to assess asthma management, which is commonly suboptimal in settings with
limited access to quality-assured essential asthma medicines.
GAN aims to progress recommendations in the GARs and produce a further report in 2018, engaging and
reinforcing the role of Government’s health ministers, the World Health Organization (WHO),
policy-makers, health-workers, those with asthma, development partners/donors and the media, in efforts
to improve asthma care globally. GANs core activities are global surveillance of asthma prevalence,
severity, management and risk factors; promotion of standard case management of asthma; operational
research; capacity building; engagement with policy makers; and access to affordable quality-assured
essential medicines.
The four main hypotheses of GAN Phase I are: 1) globally, the burden of asthma is changing in adults and
children; 2) there is large variation in the diagnosis of asthma; 3) in many locations, asthma is under-diagnosed
and its management is suboptimal; and 4) there are potentially remedial risk factors of asthma.
Methodology
Study subjects
Each GAN centre is a defined geographical area. Within each centre, subjects will be selected in the same
manner as ISAAC Phase Three. The same age groups will be used: 13/14-year-old adolescents
(self-completed questionnaires) and 6/7-year-old children (parental completed questionnaires), and GAN
Phase I adds their parents as an adult group (see next paragraph). The sampling unit will be a school for
each age group which will be selected using a table of random numbers. A minimum of 10 schools will be
required in each centre, or all schools in the sampling frame if there are fewer than 10 schools. Students of
both age groups are selected either by grade/level/year or by age group.
Additionally, GAN is recommending that the parents/guardians of the adolescents and children are also
surveyed in order to obtain symptom prevalence of asthma, rhinitis and eczema as there has been a
paucity of international prevalence data on adult asthma. The GAR 2011 and GAR 2014 reported data on
asthma in adults mainly from the World Health Survey 2003, which had small numbers of participants in
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most countries and which was a general health survey with very limited information specifically on asthma
and wheeze. In addition the adults in GAN will provide more in-depth environmental data, particularly
from the parents of the adolescent group, as the adolescents may not be able to answer some questions
relating to their early life.
Study design
GAN Phase I is a cross-sectional, multi-centre, multi-country, epidemiological research, study design. This
will meet these objectives of GAN Phase I: 1) to conduct asthma surveillance around the world in two age
groups of children, and their parents, measuring prevalence, severity, management and risk factors, using
similar methods to ISAAC Phase Three; 2) to examine time trends in prevalence, severity and risk factors
from centres participating in ISAAC Phase Three; and 3) to evaluate the appropriateness of asthma
management, especially access to quality-assured essential asthma medicines, as defined by WHO.
Methods
The methodology will be the same as ISAAC Phase Three methodology, with expansion, in particular, in
the areas of on risk factor determinants and on management of asthma. The manual containing the
information required to undertake the fieldwork is available from the GAN website [3]. Each centre has a
defined geographical area and the centres that undertook ISAAC Phase Three and/or Phase One are
expected to use the same sampling frame so that comparisons of data can be subsequently undertaken. As
in ISAAC, new centres are encouraged to join to obtain wider diverse global participation and to
encourage rural/urban comparisons. Principal investigators are identified at the registration stage which
began in November 2015. Phase I will be co-ordinated by N. Pearce (London School of Hygiene and
Tropical Medicine, London, UK) who will lead the main data centre. L. García-Marcos (IMIB Bioresearch
Institute and University of Murcia, Murcia, Spain) will lead the data centre for Spanish and Portuguese
language centres. The GAN Global Centre, will be led by I. Asher (the University of Auckland, Auckland,
New Zealand) assisted by P. Ellwood, GAN Research Manager.
An Expression of Interest form was available from 2012, from the GAN website until formal registrations
opened on November 1, 2015. As of July 1, 2016, there were expressions of interest from 344 centres in 132
countries, with formal registrations from 89 centres in 35 countries. The registration document identifies
principal investigators (two may be appointed per centre, one for adolescents and children and the other for
the adult group), and a national coordinator may be appointed if there is more than one centre in a country
and if there is an identified need. The manual contains all the necessary information needed to undertake
the fieldwork and describes the criteria required for inclusion in the worldwide data set.
The same standardised written core questionnaires, developed for ISAAC for use in Phases One and
Three, will be used in GAN. Demographic questions include the participant’s name, where allowed, age,
date of birth, school (for the adolescents and children), sex and date of interview. Questionnaires will be
coded using a unique number for each centre, school and participant to ensure confidentiality and to link
the questionnaires between the adults, adolecents and children. Collection of data regarding participants
ethnicity is optional in which case ethnic categories from local census forms should be used [26].
The written core questionnaires, used in ISAAC, have had a question about doctor-diagnosed asthma,
rhinitis and eczema added. The core questions are both sensitive and specific, have good content,
construct and concurrent and predictive validity [27]. Height and weight measurements will be taken by
the fieldworkers in schools. The environmental risk factor questionnaire, developed for ISAAC Phase
Three has been expanded for use in GAN. Not all of these questions are compulsory as indicated in the
GAN Manual. Some questions that were not considered appropriate for the adolescent group to complete
in ISAAC Phase Three have been included in the adult questionnaire. The adult symptoms questionnaire
was derived from elements from ISAAC and the European Community Respiratory Health Survey with the
aim of capturing the spectrum of chest symptoms that might be attributable to asthma in young and
middle-aged adults and the diagnostic labels applied (see the supplementary material).
As in ISAAC, a video asthma questionnaire will be an optional tool: the international version as used in
ISAAC [28]. This 6-min non-verbal video shows clinical signs of asthma symptoms and was developed by
the Wellington Asthma Research Group, to avoid problems of translation and comprehension of terms
such as “wheeze” or “whistling” and their use in culturally heterogeneous populations [29]. The video has
the advantage of obtaining data from a large number of students quickly and efficiently.
Sample size and subjects
As in ISAAC, a sample size of 3000 participants per age group (and therefore potentially 6000 adults of
each group) will be used. The sample size will provide greater than 99% (at the 1% level of significance) to
detect differences in the prevalence of wheezing of 30% in one centre and 25% in another centre [27]. As
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sampling is done by school, while the information is gained from the school pupils and adults, there is
likely to be a cluster effect. Like ISAAC, the analysis will incorporate adjustment for cluster sampling using
the design effect [30], which is important for large studies where clusters of different size may be used in
different regions. If centres are unable to obtain 3000 participants, provided they do not have fewer than
1000 per age group and fulfil the criteria described in the GAN manual, they may be included.
The mean participation in ISAAC Phase Three was 88% in adolescents and 84.5% in children. High
participation is sought for GAN Phase I: at least 80% for 13/14 year olds and 70% for 6/7 year olds and 70%
for adults/parents. For the adolescent group, a return visit to school can be made to capture the absentees
and, for the children, redistribution of questionnaires to the parents can be done once or, if necessary, twice.
Analyses
On-line documents for data entry are available from the GAN website. Once the centres have registered,
principal investigators are emailed a personalised copy of the centre report for use during fieldwork. The
centre report can be completed on-line and submitted via the website to the GAN Global centre in
Auckland, New Zealand.
At the time of conducting the survey, fieldworkers are requested to check the questionnaires for any obvious
demographic entry errors so that this information can be corrected using school records. No alteration to the
symptom and risk factor questionnaire data is allowed. Data is entered onto the computer as it is presented
on the questionnaire, preserving confidentiality by coding. At least 10% of the data must be double entered
to identify data entry errors. Centre principal investigators are responsible for their own data coding and
entry. An epi info package is available on the GAN website for investigators to use. Centres may wish to use
questionnaire scanning software such as optical mark recognition for data entry; however, procedures to deal
with data entry errors must be documented and sent to the GAN Global Centre. The software should have
the ability to export the data set as a .CSV file.
Data will be submitted to the GAN Global Centre (Auckland, New Zealand) at the same time the centre
report is submitted. The GAN Global Centre will acknowledge receipt of the data and centre report, will
undertake some quality control checks and will then send the data to one of two designated data centres.
The data centre in Murcia, led by L. García-Marcos will undertake the data checks on all Spanish- and
Portuguese-speaking centres. The data centre in London, led by N. Pearce will undertake the data checks
for centres using all other languages.
The approach to data analyses will be similar to that used in ISAAC [6]. This standardised approach is
particularly important for examination of time trends in prevalence and severity from ISAAC to GAN [31,
32], to ensure comparability. For the environmental questions, the approach used will follow that of
ISAAC [33], and assessment of time trends in risk factors will allow changes in asthma prevalence to be
analysed in relation to changes in prevalence of established risk factors within the centres which
participated in ISAAC Phase Three.
On completion of the data checks and methodology checks from the centre report, any deviations from
protocol will be examined carefully by the GAN Steering Group. Provided the deviation from protocol is
not severe enough for exclusion of the centre, the data will be included in the analyses and subsequent
publications. Protocol variations that are accepted will be footnoted in the tables of the publications. This
follows the same principles as adopted in ISAAC Phases One and Three.
Ownership of data, ethics, dissemination of results and funding
Each centre owns its own data and is free to publish these data without prior approval of the GAN
Steering Group. All worldwide publications will have a writing group “and the Global Asthma Network
Phase I Study Group”. This group, comprising all Steering Group members, national coordinators (if one
has been appointed) and principal investigators of centres included in the paper, will be named in each
paper and consulted on the paper in preparation prior to journal submission. Each centre is required to
obtain ethics approval from their local ethics committee prior to the start of their study. Each centre is
required to provide funding for the fieldwork.
Piloting of GAN Phase I
The pilot of the GAN methodology and questionnaires for the adolescent group, the children and the
parents/adults of both groups was undertaken in one school for each age group in Auckland, New
Zealand, Cartagena, Spain, and Madani, in east-central Sudan. The adolescents completed the
questionnaire at school and gave immediate feedback which enabled some question formats to be
improved. The questions were discussed with the students, for example, if they found the questions on
smoking intrusive. Most participants were appreciative of the anonymity of questionnaires, although some
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found it a bit long. For the children and for the parent/adults of both groups, the questionnaires were sent
home for completion and return (for the parent/adults, this was a new methodology). Investigators are
encouraged to include the parent/adult group, as the information provided will give new information on
adults, and additional useful family history.
Significance of GAN
GAN will expand on the ISAAC Phase Three time trends findings to explore in depth the negative and
positive associations found with the environmental risk factor data. In addition, this will be the first major
global surveillance of asthma prevalence, severity, management and risk factors which includes adults/
parents of two age groups of school children. GAN will also collect further information on the topics
addressed in the Global Asthma Reports 2011 and 2014: including asthma prevalence and severity;
diagnosis of asthma; unplanned visits including emergency room visits and hospital admissions;
management policies; and access to quality-assured essential asthma medicines. New centres from
countries that had not previously undertaken ISAAC will provide rich new information.
GAN Phase I will build on the findings of ISAAC by collecting further information on asthma, rhinitis and
eczema prevalence, severity, diagnoses, asthma emergency room visits, hospital admissions, management
and use of quality-assured essential asthma medicines. The subjects will be the same age groups as ISAAC
Phase Three, and their parents. In this first global monitoring of asthma in children and adults since 2003,
further evidence will be obtained to understand asthma, management practices and risk factors, leading to
further recognition of asthma as an important non-communicable disease and to reduce its global burden.
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